prikaz prve stranice dokumenta Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
  Download
PDF 11.56 MB
Scientific paper - Original scientific paper
Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
Oncotarget, 7 (2016), 51; 84645-84657. https://doi.org/10.18632/oncotarget.13175.
Li, Qinlong; Yin, Lijuan; Jones, Lawrence W.; Chu, Gina C-Y; Wu, Jason B-Y.; Huang, Jen-Ming; Li, Quanlin; You, Sungyong; Kim, Jayoung; Lu, Yi-Tsung; Mrđenović, Stefan; Wang, Ruoxiang; Freeman, Michael R.; Garraway, Isla; Lewis, Michael S.; Chung, Leland W. K.; Zhau, Haiyen E. More authors...

Cite this document

Li, Q., Yin, L., Jones, L. W., Chu, G. C. Y., Wu, J. B. Y., Huang, J. M. ... Zhau, H. E. (2016). Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells. Oncotarget, 7. (51), 84645-84657. doi: 10.18632/oncotarget.13175.

Li, Qinlong, et al. "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells." Oncotarget, vol. 7, no. 51, 2016, pp. 84645-84657. https://doi.org/10.18632/oncotarget.13175.

Li, Qinlong, Lijuan Yin, Lawrence W. Jones, Gina C Y Chu, Jason B Y. Wu, Jen Ming Huang, Quanlin Li, et al. "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells." Oncotarget 7, no. 51 (2016): 84645-84657. https://doi.org/10.18632/oncotarget.13175.

Li, Q., et al. (2016) 'Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells', Oncotarget, 7(51), pp. 84645-84657. doi: 10.18632/oncotarget.13175.

Li Q, Yin L, Jones LW, Chu GCY, Wu JBY, Huang JM, and sur.. Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells. Oncotarget [Internet]. 2016 [cited 2024 December 30];7(51):84645-84657. doi: 10.18632/oncotarget.13175.

Q. Li, et al., "Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells", Oncotarget, vol. 7, no. 51, pp. 84645-84657, 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:232835. [Accessed: 30 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Keratin 13 Expression Reprograms bone and Brain Metastases of Human Prostate Cancer Cells
AuthorQinlong Li
AuthorLijuan Yin
AuthorLawrence W. Jones
AuthorGina C-Y Chu
AuthorJason B-Y. Wu
AuthorJen-Ming Huang
AuthorQuanlin Li
AuthorSungyong You
AuthorJayoung Kim
AuthorYi-Tsung Lu
AuthorStefan Mrđenović
MBZ: 103524
AuthorRuoxiang Wang
AuthorMichael R. Freeman
AuthorIsla Garraway
AuthorMichael S. Lewis
AuthorLeland W. K. Chung
AuthorHaiyen E. Zhau
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Lethal progression of prostate cancer metastasis can be improved by developing animal models that recapitulate the clinical conditions. We report here that cytokeratin 13 (KRT13), an intermediate filament protein, plays a directive role in prostate cancer bone, brain, and soft tissue metastases. KRT13 expression was elevated in bone, brain, and soft tissue metastatic prostate cancer cell lines and in primary and metastatic clinical prostate, lung, and breast cancer specimens. When KRT13 expression was determined at a single cell level in primary tumor tissues of 44 prostate cancer cases, KRT13 level predicted bone metastasis and the overall survival of prostate cancer patients. Genetically enforced KRT13 expression in human prostate cancer cell lines drove metastases toward mouse bone, brain and soft tissues through a RANKL-independent mechanism, as KRT13 altered the expression of genes associated with EMT, stemness, neuroendocrine/neuromimicry, osteomimicry, development, and extracellular matrices, but not receptor activator NF-κB ligand (RANKL) signaling networks in prostate cancer cells. Our results suggest new inhibitors targeting RANKL-independent pathways should be developed for the treatment of prostate cancer bone and soft tissue metastases.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleOncotarget
Numberingvol. 7, no. 51, pp. 84645-84657
e-ISSN1949-2553
DOIhttps://doi.org/10.18632/oncotarget.13175.
URN:NBNurn:nbn:hr:239:232835
Publication2016
Document URLhttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13175&path[]=41769
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 3.0 Unported (CC BY 3.0) icon
Created on2019-11-27 12:07:03